Late adverse reactions to intravascular iodine based contrast media: an update

Definition Late adverse reactions (LAR) to contrast media (CM) are defined as reactions occurring 1 h to 1 week after exposure. Need for review In view of more prospective studies of LAR and new data about their pathophysiology, the Contrast Medium Safety Committee (CMSC) of the European Society of...

Full description

Saved in:
Bibliographic Details
Published inEuropean radiology Vol. 21; no. 11; pp. 2305 - 2310
Main Authors Bellin, Marie-France, Stacul, Fulvio, Webb, Judith A. W., Thomsen, Henrik S., Morcos, Sameh K., Almén, Torsten, Aspelin, Peter, Clement, Olivier, Heinz-Peer, Gertraud, Reimer, Peter, van der Molen, Aart
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer-Verlag 01.11.2011
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN0938-7994
1432-1084
1432-1084
DOI10.1007/s00330-011-2200-9

Cover

More Information
Summary:Definition Late adverse reactions (LAR) to contrast media (CM) are defined as reactions occurring 1 h to 1 week after exposure. Need for review In view of more prospective studies of LAR and new data about their pathophysiology, the Contrast Medium Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) reviewed the literature on LAR and updated their guidelines. Clinical features and pathology LAR after CM include symptoms such as nausea, vomiting, headache, itching, skin rash, musculoskeletal pain, and fever. Skin reactions are well-documented LAR to CM with an incidence of approximately 2%–4% after nonionic monomers. LAR are commoner by a factor of three to four after nonionic dimers. The commonest skin reactions are maculopapular rashes, erythema and skin swelling. These reactions are T cell-mediated immune reactions, and the diagnosis may be confirmed using skin tests (patch or delayed reading intradermal). The main risk factors for LAR are a previous reaction to contrast medium, a history of allergy, and interleukin-2 treatment. Most skin reactions are mild or moderate and self-limiting. Management Management is symptomatic and similar to the management of other drug-induced skin reactions. To reduce the risk of repeat reactions avoidance of the relevant CM and any cross-reacting agents identified by skin testing is recommended.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:0938-7994
1432-1084
1432-1084
DOI:10.1007/s00330-011-2200-9